Cora’s goal is to see her granddaughter splash through more puddles.
Could ERBITUX + encorafenib help your patients like Cora with BRAF V600E MT mCRC reach their similar goal?
mCRC with BRAF V600E mutation patient case*
Cora is a patient who has mCRC with a BRAF V600E mutation.
- 59-year-old female with a history of hypertension, controlled with an ACE inhibitor
- Previously diagnosed with mCRC
- Genetic testing, including for BRAF mutation, identified her mCRC as positive for BRAF V600E mutation
- Tumor was KRAS WT; NGS found no RAS mutations
- Her physician prescribed 1L bevacizumab + FOLFOX for the treatment of her mCRC
- 5 months after her initial diagnosis, she presents to her physician with rapidly worsening symptoms
Laboratory results and medical findings
- CT scan reveals a 3.5-cm nonobstructing tumor and multiple new liver and peritoneal metastases
- ECOG PS 1
- Cora’s family is realistic, yet hoping for an improvement in her symptoms, a slowing of her disease progression, and more time
- Cora understands her prognosis but is determined to keep fighting
*Hypothetical patient case study.
SELECT IMPORTANT SAFETY INFORMATION
- ERBITUX can cause interstitial lung disease (ILD). ILD, which was fatal in one case, occurred in <0.5% of 1570 patients receiving ERBITUX in clinical trials. Monitor patients for signs and symptoms of pulmonary toxicity. Interrupt or permanently discontinue ERBITUX for acute onset or worsening of pulmonary symptoms. Permanently discontinue ERBITUX for confirmed ILD.